| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/30/2000 | EP0612246B1 Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones |
| 08/30/2000 | EP0584287B1 Purification of müllerian inhibiting substance for treatment of certain tumors |
| 08/30/2000 | CN1265149A Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment |
| 08/30/2000 | CN1265038A Cellular vesicle called 'exosome', prepn. and use thereof in immune stimulation |
| 08/30/2000 | CN1265037A Soya extract, process for its prepn. and pharmaceutical compsn. |
| 08/30/2000 | CN1264583A Active aloe powder and preparing process thereof |
| 08/30/2000 | CN1264580A Application of tanshinone in preparing medicine for treating tumor |
| 08/30/2000 | CN1055926C New acronycine analogues, process for their prepn. and pharmaceutical compsns. containing them |
| 08/30/2000 | CN1055921C Derivative of vitamin D system which is modified in 20-position, prepn. of same and pharmaceutical made of same |
| 08/30/2000 | CN1055920C Aklyl benzoylguanidines derivatives |
| 08/30/2000 | CN1055839C Prepn. for treating cancer and its preparing process |
| 08/30/2000 | CN1055832C Capsule of cartilage powder of shark and prepn. thereof |
| 08/30/2000 | CN1055826C Anti-cancer food compsn. capsule and prepn. method thereof |
| 08/29/2000 | US6111109 Cyclizing a 2-(2-alkyloxycarbonylphenyl)amino-)benzaldehyde by treating with a boron trifluoride; neutralization of the formed salt; amidation with an 2-n,n-dialkylaminoethylamine;antitumor and -carcinogenic |
| 08/29/2000 | US6111084 Sialyl lewis mimetics produced by solid phase synthesis; antiinflammatory agents |
| 08/29/2000 | US6110964 For treating arthritis, inflammatory bowel disease, crohn's disease, emphysema, acute respiratory distress syndrome, asthma chronic obstructive pulmonary disease, alzheimer's disease, organ transplant toxicity, cachexia, cancer |
| 08/29/2000 | US6110957 Antitumor agent treating cell proliferative disorders such as cancer, dyes, fungicides, bactericides |
| 08/29/2000 | US6110953 A therapeutic drug mixture comprising a 1h-1,2,4-triazole with a chemotherapeutic agents can both reduce and suppress the growth of cancers, tumors and leukemia; synergistic effect |
| 08/29/2000 | US6110939 As a substance p antagonists treating tachykinin-mediated disease, asthma, central nervous system disorder |
| 08/29/2000 | US6110929 Immunomodulators which induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor and inhibit t-helper-type 2 immune response; for treatment of viral and neoplastic diseases |
| 08/29/2000 | US6110924 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds |
| 08/29/2000 | US6110923 Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
| 08/29/2000 | US6110896 Peptidyl compounds and their therapeutic use |
| 08/29/2000 | US6110889 Administering hexapeptides of amino acid sequence arg-arg-trp-trp-cys-arg to inhibit alpha-chemokine binding to the tumor cell |
| 08/29/2000 | US6110747 Compounds and methods for modulating tissue permeability |
| 08/29/2000 | US6110740 Human vault RNA |
| 08/29/2000 | US6110721 Isolated polypeptide at least about 80% homologous to and possesses at least one immune epitope of thrombin reference amino acid sequence; anticoagulants and procoagulants; diagnosis of blood disorders; drug screening; antitumor agents |
| 08/29/2000 | US6110701 DNA encoding precursor of interleukin-1β converting enzyme--related cysteine proteinase II (ICErel -II) |
| 08/29/2000 | US6110694 Methods for determining complexes of tumor rejection antigens and HLA-Cw*160/molecules |
| 08/29/2000 | US6110686 DNA hybridizing to a human cystatin-like protein (CSTIN) |
| 08/29/2000 | US6110461 Reovirus for the treatment of neoplasia |
| 08/29/2000 | US6110458 Cancer therapy utilizing ex vivo gene transduction |
| 08/24/2000 | WO2000049147A1 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy |
| 08/24/2000 | WO2000049144A2 Pyk2 binding proteins |
| 08/24/2000 | WO2000049045A1 Peptide variants of the tumour marker muc1 and the use thereof |
| 08/24/2000 | WO2000049030A1 5-fluorouridine derivatives and anticancer agents containing the same as the active ingredient |
| 08/24/2000 | WO2000049021A2 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
| 08/24/2000 | WO2000049018A1 2-amino-6-anilino-purines and their use as medicaments |
| 08/24/2000 | WO2000049013A1 Isothio cyanato alkylthiophenes as cancer chemoprotective agents |
| 08/24/2000 | WO2000048996A2 β-ALANINE DERIVATIVES |
| 08/24/2000 | WO2000048639A1 Immobilized labeling compounds and methods |
| 08/24/2000 | WO2000048632A1 Novel redox clamping agents and uses thereof |
| 08/24/2000 | WO2000048630A1 Immunogenic complexes and methods relating thereto |
| 08/24/2000 | WO2000048629A1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS |
| 08/24/2000 | WO2000048628A1 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral, antiparasitic or antitumoral cytotoxic response |
| 08/24/2000 | WO2000048627A1 Inhibitors of separin, method for identifying them and uses |
| 08/24/2000 | WO2000048623A1 Novel amide derivatives as growth hormone secretagogues |
| 08/24/2000 | WO2000048621A2 Methods and compositions for regulating protein-protein interactions |
| 08/24/2000 | WO2000048616A1 High molecular weight extracts of $i(convolvulus arvensis )(field bindweed) |
| 08/24/2000 | WO2000048614A2 Method for producing anti-tumor th1 cells |
| 08/24/2000 | WO2000048611A1 Liposome preparations containing antitumor drug |
| 08/24/2000 | WO2000048610A1 Chemical compounds |
| 08/24/2000 | WO2000048609A1 Chemical compounds |
| 08/24/2000 | WO2000048606A1 Compositions and methods for use in targeting vascular destruction |
| 08/24/2000 | WO2000048604A1 Utilization of dienogest in high doses |
| 08/24/2000 | WO2000048603A1 DIBENZO-AZEPINE DERIVATIVES AS αV INTEGRIN RECEPTOR ANTAGONISTS |
| 08/24/2000 | WO2000048595A1 A novel anti-angiogenic agent comprising at least one kringle region and an upstream pre-activation domain of plasminogen |
| 08/24/2000 | WO2000048594A1 Use of lipoic acid combination with ascorbic acid in the treatment of cancer |
| 08/24/2000 | WO2000048593A1 Epoxide hydrolase complexes and methods therewith |
| 08/24/2000 | WO2000048591A1 Combinations for the treatment of diseases involving angiogenesis |
| 08/24/2000 | WO2000048590A1 Substituted stilbene compounds with vascular damaging activity |
| 08/24/2000 | WO2000048586A1 Remedies |
| 08/24/2000 | WO2000048581A2 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| 08/24/2000 | WO2000048577A1 Medicament for the treatment and prevention of cancer of the intestine |
| 08/24/2000 | WO2000048571A1 Spontaneously dispersible n-benzoyl staurosporine compositions |
| 08/24/2000 | WO2000031051B1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 08/24/2000 | WO2000022113A9 ENZYMATIC SYNTHESIS OF ssDNA |
| 08/24/2000 | WO2000018440A8 Somatostatin receptor radioligand with increased uptake |
| 08/24/2000 | WO2000015246A9 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 08/24/2000 | WO1999067379A3 Structured antisense nucleic acid molecules |
| 08/24/2000 | WO1999042828A3 Treating cancer |
| 08/24/2000 | WO1999034763A3 Pharmaceutical compositions comprising thiram for inhibiting angiogenesis |
| 08/24/2000 | WO1998000439A3 Multivalent compounds for cross-linking receptors and uses thereof |
| 08/24/2000 | DE4193302C2 Verwendung rekombinanter Antikörper spezifisch für TNF-alpha Using recombinant antibody specific for TNF-alpha |
| 08/24/2000 | DE19906744A1 Pharmaceutical composition useful for tumor therapy comprises tumor-reactive helper T cells that produce high levels of interferon gamma and little or no interleukin-4 |
| 08/24/2000 | CA2541869A1 Compositions and methods for use in targeting vascular destruction |
| 08/24/2000 | CA2455956A1 Compositions and methods for use in targeting vascular destruction |
| 08/24/2000 | CA2372059A1 Use of an ompa enterobacterium protein associated with the elagigiltv peptide for treating melanomas |
| 08/24/2000 | CA2371872A1 Methods and compositions for regulating protein-protein interactions |
| 08/24/2000 | CA2371824A1 .beta.-alanine derivatives |
| 08/24/2000 | CA2368309A1 Peptide variants of the tumour marker muc1 and the use thereof |
| 08/24/2000 | CA2363670A1 Chemical compounds |
| 08/24/2000 | CA2362970A1 Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy |
| 08/24/2000 | CA2362943A1 Pyk2 binding proteins |
| 08/24/2000 | CA2362860A1 Immobilized labeling compounds and methods |
| 08/24/2000 | CA2362787A1 Novel redox clamping agents and uses thereof |
| 08/24/2000 | CA2362334A1 Dibenzo-azepine derivatives as .alpha.v integrin receptor antagonists |
| 08/24/2000 | CA2362330A1 A novel anti-angiogenic agent comprising at least one kringle region and an upstream pre-activation domain of plasminogen |
| 08/24/2000 | CA2362306A1 Chemical compounds |
| 08/24/2000 | CA2362290A1 Novel amide derivatives as growth hormone secretagogues |
| 08/24/2000 | CA2362288A1 Use of lipoic acid combination with ascorbic acid in the treatment of cancer |
| 08/24/2000 | CA2362192A1 Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral, antiparasitic or antitumoral cytotoxic response |
| 08/24/2000 | CA2362136A1 High molecular weight extracts of convolvulus arvensis (field bindweed) |
| 08/24/2000 | CA2361278A1 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
| 08/24/2000 | CA2360353A1 2-amino-6-anilino-purines and their use as medicaments |
| 08/23/2000 | EP1029863A1 Novel camptothecin derivatives |
| 08/23/2000 | EP1029853A1 Heteroaromatic bicyclic derivatives useful as anticancer agents |
| 08/23/2000 | EP1029547A1 Pharmaceutically active compounds and method for identifying same |
| 08/23/2000 | EP1029540A2 Use of droloxifene for the treatment of cardiovascular diseases |
| 08/23/2000 | EP1029245A1 Prognostic protocol |